July 29 2020
The Most Recent Study Posted
Late treatment study Source Study Page
D'Arminio Monforte et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.07.056 (Letter)
Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?
HCQ+AZ adjusted death HR 0.44, p=0.009. Propensity scores include baseline COVID-19 disease severity, age, gender, number of comorbidities, cardio-vascular disease, duration of symptoms, date of admission, baseline plasma CRP. IPW censoring. Retrospective study of 539 COVID-19 hospitalized patients in Milan, with treatment a median of 1 day after admission. HCQ 197 patients, HCQ+AZ 94, control 92. Control group received various other treatments. Authors excluded people receiving other drugs which could have biased the effect of HCQ when used in combination. Residual confounding is possible (e.g., people with CVD were more frequent in control), however people in the control group were more likely to require mechanical ventilation.